Evidence map›Paper›PMID 42851168›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.

Jennifer L Whitwell, Jerusha G Bhaskaran, Ryota Satoh, Jonathan Graff-Radford, Mary M Machulda, Val J Lowe, Michelle M Mielke, Dennis W Dickson, Shin-Cheng Tzeng, John Bui and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jerusha G BhaskaranDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Ryota SatohDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University, Winston-Salem, North Carolina, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Shin-Cheng TzengC2N Diagnostics, C2N Diagnostics LLC, St. Louis, Missouri, USA.
John BuiC2N Diagnostics, C2N Diagnostics LLC, St. Louis, Missouri, USA.
Philip B VergheseC2N Diagnostics, C2N Diagnostics LLC, St. Louis, Missouri, USA.
Tim WestC2N Diagnostics, C2N Diagnostics LLC, St. Louis, Missouri, USA.
Venky VenkateshC2N Diagnostics, C2N Diagnostics LLC, St. Louis, Missouri, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
NIA NIH HHS R01 AG050603NIH HHS R01-AG50603
6 · The paper itself

Abstract

introductionThe concentration of endogenous tau microtubule-binding region containing residue-243 in plasma (eMTBR-tau243) has been proposed to be a sensitive biomarker of tangle pathology in Alzheimer's disease (AD). We assessed eMTBR-tau243 and phosphorylated tau217 (p-tau217) with tau and Aβ-positron emission tomography (PET) across different AD clinical phenotypes.

methodsPlasma eMTBR-tau243, p-tau217, and the ratio of non-phosphorylated to phosphorylated tau217 (%p-tau217) were measured in 20 Aβ-PET positive AD patients representing four clinical phenotypes and 10 cognitively unimpaired controls. Plasma levels were correlated with PET, demographic and cognitive variables.

resultsPlasma eMTBR-tau243, p-tau217, and %p-tau217 levels were greater in AD than controls, with greatest levels observed in motor-predominant AD. Plasma biomarker levels correlated with cortical flortaucipir-PET uptake; eMTBR-tau243 correlations were strongest. In AD, eMTBR-tau243 levels were undetectable in patients with mild/focal flortaucipir-PET uptake (45%). Only eMTBR-tau243 correlated with cognition. DISCUSSION: Plasma eMTBR-tau243 may be an excellent biomarker for tau deposition and cognition in AD across different phenotypes.

Indexed as

Alzheimer Diseasetau ProteinsAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrainFemaleHumansMalePhenotypePhosphorylationPositron-Emission TomographyAmyloid beta-PeptidesBiomarkerstau Proteinsatypical Alzheimer's diseasecorticobasal syndromeflortaucipirlogopenicplasma biomarkerspositron emission tomographyposterior cortical atrophy

Identifiers

PMID42851168
PMCPMC13650602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.